Balanced biology. Lasting relief.
A potential new way to calm
atopic dermatitis—for longer relief.
ENS-002, a trio of beneficial bacteria, tackle the hidden microbial triggers underlying atopic dermatitis, potentially bringing lasting relief with a better safety profile.
No more whack-a-mole with atopic dermatitis.
For people with atopic dermatitis (AD), the struggle never stops. Constant itch, recurring flares, and persistent skin irritation remain top patient concerns. Despite countless treatments, there is still no option that provides safe, tolerable, and lasting relief for mild-to-moderate AD.
S. aureus is implicated in 70–83% of AD flares, but its role remains under-addressed by modern therapeutics.
Just before an AD flare, S. aureus surges, releasing proteases and toxins that weaken the skin barrier and elicit the immune response. Targeting the microbial drivers of AD opens the door to a new class of treatments that could work alongside immunosuppressants and emollients for more comprehensive, lasting relief.
ENS-002 pacifies S. aureus virulence as a potential therapeutic for atopic dermatitis.
ENS-002, or “Ensemble No.2,” is a trio of topical bacteria that neutralizes S. aureus virulence on the skin. Designed for long-term relief, ENS-002 aims to prevent AD flares without the side effects of traditional treatments—making it suitable for all ages and severities.
ENS-002 was discovered at Concerto Biosciences by testing how millions of different microbial community compositions affect S. aureus behavior. Learn more about the platform behind ENS-002.
A Phase 1b trial has been completed to evaluate ENS-002’s safety and mechanism of action in people with atopic dermatitis.
Led by experience, backed by vision.
Fermata has the experience, vision, and skills to succeed in dermatology.
Leadership
John Koconis, MBA
Chief Executive Officer
Joseph Lucchese
Financial ConsultantScientific Advisory Board
Peter Lio, MD
Scientific Advisory Board Member
Tiffany Scharschmidt, MD
Scientific Advisory Board Member